Edwards Lifesciences (NYSE:EW) Upgraded by Wall Street Zen to "Strong-Buy" Rating

Key Points

• Edwards Lifesciences has been upgraded to a "strong-buy" rating by Wall Street Zen, elevating its previous "buy" status.
• Several analysts have raised their price targets for the stock, with Piper Sandler increasing it from $83.00 to $90.00, and Mizuho from $87.00 to $95.00.
• The company reported a quarterly EPS of $0.67, exceeding estimates, with revenue of $1.53 billion, marking an 11.9% increase year-over-year.

Edwards Lifesciences (NYSE:EW - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "buy" rating to a "strong-buy" rating in a note issued to investors on Sunday.

Other equities research analysts also recently issued reports about the stock. Piper Sandler lifted their price target on shares of Edwards Lifesciences from $83.00 to $90.00 and gave the company an "overweight" rating in a research report on Friday, July 25th. William Blair upgraded shares of Edwards Lifesciences to a "strong-buy" rating in a research report on Friday, July 25th. Royal Bank Of Canada lifted their price target on shares of Edwards Lifesciences from $85.00 to $89.00 and gave the company an "outperform" rating in a research report on Friday, July 25th. Mizuho raised their price objective on shares of Edwards Lifesciences from $87.00 to $95.00 and gave the stock an "outperform" rating in a research note on Friday, July 25th. Finally, Robert W. Baird raised their price objective on shares of Edwards Lifesciences from $78.00 to $79.00 and gave the stock a "neutral" rating in a research note on Friday, July 25th. Three investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $87.17.

Edwards Lifesciences Price Performance

EW stock opened at $74.39 on Friday. The firm has a 50 day moving average of $78.69 and a 200-day moving average of $75.53. Edwards Lifesciences has a 12-month low of $64.00 and a 12-month high of $83.00. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. The company has a market cap of $43.67 billion, a price-to-earnings ratio of 10.70, a PEG ratio of 3.59 and a beta of 1.07.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The company had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.49 billion. During the same period last year, the firm earned $0.70 EPS. The company's revenue for the quarter was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, equities analysts expect that Edwards Lifesciences will post 2.45 EPS for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In other news, insider Larry L. Wood sold 8,950 shares of the business's stock in a transaction on Monday, August 18th. The shares were sold at an average price of $78.06, for a total transaction of $698,637.00. Following the completion of the sale, the insider directly owned 206,900 shares of the company's stock, valued at $16,150,614. The trade was a 4.15% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP Daniel J. Lippis sold 4,114 shares of the business's stock in a transaction on Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the sale, the vice president directly owned 22,002 shares of the company's stock, valued at $1,748,278.92. This represents a 15.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.29% of the stock is owned by insiders.

Hedge Funds Weigh In On Edwards Lifesciences

Several hedge funds and other institutional investors have recently made changes to their positions in EW. Norges Bank acquired a new position in shares of Edwards Lifesciences during the 2nd quarter valued at $580,640,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its holdings in shares of Edwards Lifesciences by 111.2% during the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 9,129,357 shares of the medical research company's stock valued at $714,006,000 after acquiring an additional 4,805,819 shares in the last quarter. Nuveen LLC acquired a new position in shares of Edwards Lifesciences during the 1st quarter valued at $330,881,000. Marshall Wace LLP lifted its holdings in Edwards Lifesciences by 127.5% in the 2nd quarter. Marshall Wace LLP now owns 6,895,579 shares of the medical research company's stock worth $539,303,000 after buying an additional 3,864,908 shares in the last quarter. Finally, Jennison Associates LLC lifted its holdings in Edwards Lifesciences by 34.3% in the 1st quarter. Jennison Associates LLC now owns 10,086,033 shares of the medical research company's stock worth $731,036,000 after buying an additional 2,576,383 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company's stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.